Prostate Cancer Clinical Trial
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer
Summary
The purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.
Eligibility Criteria
Inclusion Criteria:
Prostate cancer.
Gleason score 2-6 or 7.
PSA ≤ 20 ng/ml.
Exclusion Criteria:
Previous prostate cancer surgery or pelvic radiation.
Prior/concurrent systemic chemotherapy for prostate cancer.
Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum.
History of hip replacement.
Prior intrapelvic surgery.
Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its uses during radiation.
Receiving continuous and current anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), dabigatran etexilate mesylate (Pradaxa),enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Jacksonville Florida, 32209, United States
How clear is this clinincal trial information?